Educational information only. Not medical advice.

Research Memos

Epitalon vs FOXO4-DRI

Epitalon studies focus on telomere maintenance, while FOXO4-DRI studies test removal of senescent cells. Separate mouse results, failed cartilage improvement and a pulmonary-vessel harm signal do not establish which would improve human aging. Neither has a validated human blood half-life in the sources reviewed here.

Research reviewed October 15, 2026. Educational information only.

Two different ways of studying aging-related biology

Epitalon and FOXO4-DRI have been discussed in aging research because they influence different cell processes. Epitalon is the tetrapeptide Ala–Glu–Asp–Gly, or AEDG. FOXO4-DRI is a synthetic peptide using D-amino acids in reversed order, called D-retro-inverso, derived from part of FOXO4 and joined to a component that helps it enter cells. Its intended effect in the original work was to eliminate certain senescent cells through programmed cell death. FDA’s 2026 Epitalon evaluation and Baar et al. (2017) establish the material distinctions.

Telomeres are protective DNA structures at chromosome ends. Some Epitalon experiments ask whether cells maintain or lengthen them. Senescence is a state in which stressed cells stop dividing but can continue to release signals. FOXO4-DRI experiments ask whether removing some of those cells changes tissue function. No study identified here directly assigned Epitalon and FOXO4-DRI to comparable groups within one experiment. Their results therefore cannot establish which extends human life more.

The main differences

What are the two experimental materials?

These identities refer to the compounds in the cited experiments. Endogenous FOXO4 is a different material from FOXO4-DRI, and related pineal extracts are different preparations from AEDG.

Epitalon

Epitalon is the four-amino-acid peptide Ala–Glu–Asp–Gly, also called AEDG. Free base and acetate are separately described forms.

Sources

FOXO4-DRI

FOXO4-DRI is a synthetic D-retro-inverso peptide based on part of the FOXO4–p53 interaction and joined to a cell-entry component. The original construct was a 46-amino-acid D-form peptide.

Sources

What happened to the cells that researchers studied?

The Epitalon studies compared treated cultures with cells grown without Epitalon and measured telomeres. The original FOXO4-DRI work compared senescent-cell cultures with and without the peptide and used a corresponding L-form comparator. These are separate experiments.

Epitalon

In the 2025 study, normal fibroblast telomeres did not lengthen after four days but lengthened after three weeks compared with untreated cells. Telomerase activity rose in normal-cell models; breast-cancer cell results implicated an alternative telomere-lengthening pathway. Figures 1–3 were corrected.

Sources

FOXO4-DRI

FOXO4-DRI promoted programmed death in senescent cells in the original systems, with p53 leaving the nucleus. Later structural measurements showed direct peptide binding to a flexible p53 region.

Sources

What did the mouse outcomes establish about aging?

Anisimov followed female Swiss-derived SHR mice given Epitalon or saline to natural death. Baar compared FOXO4-DRI with phosphate-buffered saline in separate rapid-aging and naturally aged mice, measuring organ markers. Different populations and outcomes prevent an efficacy ranking.

Epitalon

In 54 Epitalon-treated and 54 saline-control mice, mean lifespan did not change. Mean lifespan in the last tenth of survivors rose 13.3%, and maximum lifespan rose 12.3%. These are survival-tail outcomes.

Sources

FOXO4-DRI

Blood urea fell in rapid-aging and naturally aged mice; creatinine also fell in naturally aged mice. Those are waste products used to assess kidney filtering. The experiment did not establish lifespan extension.

Sources

Is there a measured human blood half-life to compare?

A blood half-life requires concentration sampling after administration of an identified preparation. Cell staining and the duration of a later biological response measure different events.

Epitalon

FDA’s 2026 evaluation described a preliminary fluorescent-label distribution experiment in pregnant rabbits, without showing that tissue fluorescence specifically represented intact Epitalon. No additional PK studies were identified; these sources do not provide a validated human blood half-life.

Sources

FOXO4-DRI

Detection inside cultured cells for at least 72 hours did not measure elimination from blood. The selected reports do not supply a validated human blood half-life, clearance or absorption profile.

Sources

Which safety findings change the interpretation?

Neither set of experiments establishes long-term clinical safety. The following findings concern different risks and cannot rank the peptides by safety.

Epitalon

Epitalon altered telomere-maintenance pathways in cancer-cell cultures as well as normal cells. This raises a biological safety question without estimating cancer risk in treated people; FDA identified substantial human safety gaps.

Sources

FOXO4-DRI

In one genetically altered mouse model, treatment was associated with loss of cells lining lung vessels and adverse lung-circulation changes. Clearing senescent expanded cartilage cells also failed to improve later cartilage formation.

Sources

Longer telomeres were measured in cells outside the body

Khavinson et al. (2003) reported telomerase activity and telomere elongation in cultured human somatic cells. Telomerase is an enzyme that can add DNA repeats to chromosome ends. Calling the cells human identifies their origin; no person received treatment in that experiment.

Al-dulaimi et al. (2025) later compared normal epithelial and fibroblast cells with breast-cancer cell lines. Normal-cell telomeres lengthened alongside increased telomerase activity. Cancer-cell results implicated alternative lengthening of telomeres, a different maintenance pathway. The normal fibroblasts had no observed telomere increase after four days; a later three-week exposure produced an increase. The paper’s published correction replaces Figures 1–3. These results do not quantify cancer incidence or clinical benefit in people.

Removing senescent cells did not always improve the next outcome

Baar et al. (2017) found that FOXO4-DRI displaced p53, a stress-response protein, from its interaction with FOXO4 and promoted death in senescent-cell cultures. The corresponding L-form peptide did not reproduce this effect. Bourgeois et al. (2025) subsequently located direct binding on a flexible p53 region. This is a specific molecular mechanism, with no implication that every senescent cell in a living person should be removed.

A downstream tissue test illustrates the distinction. Huang et al. (2021) treated extensively expanded human cartilage cells and removed more than half of the cells. Senescence-associated measurements fell, but the surviving cells did not form cartilage better than untreated expanded cells. A successful cell-clearance measurement therefore did not guarantee the functional outcome the researchers wanted.

Mouse survival and kidney measurements answer different questions

Anisimov et al. (2003) followed 54 female Swiss-derived SHR mice given Epitalon and 54 given saline from three months of age to natural death. Whole-group mean lifespan did not change. Mean lifespan among the last tenth of survivors increased 13.3%, and maximum lifespan increased 12.3%. The survival-tail result describes the longest-lived animals; it cannot be substituted for an increase in average survival.

In Baar et al. (2017), FOXO4-DRI reduced blood urea in DNA-repair-deficient rapid-aging mice and naturally aged mice; the latter also had lower creatinine. These waste products inform kidney filtering function. The rapid-aging mice showed improved wheel activity, while naturally aged animals had too much variation for a meaningful wheel experiment. The study did not establish lifespan extension. Neither paper creates a shared survival comparison between the peptides.

The missing blood measurements prevent a duration comparison

The FDA’s 2026 Epitalon evaluation described a preliminary fluorescent-label distribution experiment in pregnant rabbits. Fluorescence appeared in several maternal and fetal tissues one hour after an intravenous exposure, but the experiment did not establish that the signal specifically represented intact Epitalon. FDA identified no additional PK or toxicokinetic studies. This does not provide a validated human concentration-over-time profile or elimination half-life for an administered Epitalon preparation.

Baar et al. (2017) detected FOXO4-DRI-associated staining inside cultured cells for at least 72 hours. That observation follows direct cell exposure and does not measure intact peptide in circulating blood. The selected FOXO4-DRI studies provide no validated human blood half-life. Molecular design, treatment intervals and later tissue responses cannot determine which peptide remains in human blood longer.

The safety questions arise from the actual biology

Epitalon’s effects on normal and malignant-cell telomere maintenance leave a meaningful biological question about long-term safety. The cell studies did not measure whether treated people developed cancer. FDA’s evaluation also found insufficient human safety information to characterize the proposed compounds. Al-dulaimi et al. (2025), correction and FDA (2026) support different parts of this assessment.

For FOXO4-DRI, Born et al. (2023) reported loss of pulmonary endothelial cells—the cells lining lung vessels—and adverse lung-circulation changes in serotonin-transporter-overexpressing mice. The abstract does not provide a peptide-specific pressure change. Its numerical pressure and heart-enlargement findings are described for separate genetic-clearance or ABT263 comparisons. This organ-specific adverse observation prevents treating senescent-cell clearance as universally restorative.

The clinically useful question is whether a defined preparation improves an outcome that matters to people at an acceptable risk. Cell telomere length, cell death and mouse kidney markers help explain mechanisms and guide experiments. They have not established that either peptide extends healthy human life.

Frequently asked questions

Are Epitalon and FOXO4-DRI competing senolytics?

FOXO4-DRI was developed to trigger death in certain senescent cells. The Epitalon studies discussed here focused on telomere maintenance and separate animal outcomes. They do not establish equivalent targets or a direct senolytic comparison.

Did a mouse study show that Epitalon increases average lifespan by 12.3%?

The 12.3% figure describes maximum lifespan in one female-mouse study. Mean lifespan did not change, while the mean among the last tenth of survivors rose 13.3%. Each statistic describes a different part of the survival distribution.

Does the FOXO4-DRI kidney result show whole-body rejuvenation?

The investigators measured blood waste products and kidney tissue, alongside some physical observations. These findings support a kidney-related effect in those mice. They do not measure whole-body age reversal or longer human life.

Does telomere lengthening prove better health?

The experiment must also measure the health outcome. In the 2025 Epitalon study, normal and cancer-cell models used different telomere-maintenance pathways. The study did not test physical function, disease prevention or survival in treated people.

Has a direct trial identified which peptide is better for longevity?

No direct comparison was identified. The studies used different materials, species, controls and outcomes; they cannot establish a human longevity ranking.

Epitalon — full profile · Selected studies

FOXO4-DRI — full profile · Selected studies

Compare other compounds · Explore the guide previews

References

  1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590–592. doi:10.1023/A:1025493705728.

    Original PubMed record accessed 2026-10-15; design and identity retained from verified baseline pmid-12937682. No new numerical claim. Abstract; human fetal fibroblasts, telomerase and telomere results.

  2. Al-dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. doi:10.1007/s10522-025-10315-x.

    Original publisher full text accessed 2026-10-15, with original correction; baseline report id pmid-40908429 retained. Results telomere length, telomerase activity and ALT; original article read with published correction.

  3. Al-dulaimi S, Thomas R, Matta S, Roberts T. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2026;27:1. Published online November 15, 2025. doi:10.1007/s10522-025-10326-8.

    Original publisher correction full text accessed 2026-10-15. Correction text; corrected Figures 1–3 captions; PMID41240216.

  4. Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193–202. doi:10.1023/A:1025114230714.

    Original PubMed indexed abstract and author-hosted original manuscript https://khavinson.info/downloads/2003-Anisimov.pdf accessed 2026-10-15. Baseline pmid-14501183 retained. Abstract; author-hosted original manuscript Table3;54 female mice per group, saline control, mean versus survival-tail outcomes.

  5. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Epitalon-related Bulk Drug Substances: Epitalon (Free Base) and Epitalon Acetate. Briefing material for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting.

    Complete original FDA64-page PDF accessed 2026-10-15; section-specific text checked. PDF p29, b. Pharmacokinetics/Toxicokinetics: Lapina2005 rabbit fluorescent label, nonspecific tissue signal, no additional PK/toxicokinetic studies; pp7–8 identity; Human Safety.

  6. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132–147.e16. doi:10.1016/j.cell.2017.02.031.

    Original PMC full text accessed 2026-10-15 after intermittent browser challenges. Identity, Results and figure legends read; no laboratory instructions reproduced. Results Figures 2–7; STAR Methods, FOXO4 D-Retro-Inverso peptide development; Discussion initial safety limits.

  7. Bourgeois B, Spreitzer E, Platero-Rochart D, Paar M, Zhou Q, Usluer S, de Keizer PLJ, Burgering BMT, Sánchez-Murcia PA, Madl T. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications. 2025;16:5672. doi:10.1038/s41467-025-60844-9.

    Original PubMed abstract and original publisher/PMC indexed full-text sections accessed 2026-10-15. Abstract; Results and Discussion concerning p53 TAD2 and the TAT contribution; PMID40593617.

  8. Huang Y, He Y, Makarczyk MJ, Lin H. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology. 2021;9:677576. doi:10.3389/fbioe.2021.677576.

    Original PubMed abstract and original Frontiers PDF accessed 2026-10-15. Donor-count discrepancy is recorded in source-check.md. Abstract; original journal PDF Results and conclusion; population doubling levels 3 and 9.

  9. Born E, Lipskaia L, Breau M, et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023;147(8):650–666. doi:10.1161/CIRCULATIONAHA.122.058794.

    Complete original PubMed abstract accessed 2026-10-15; publisher PDF indexed abstract also checked. Complete peptide-arm methods and numeric results unavailable. Abstract Methods/Results/Conclusions, especially SM22-5-HTT+ arm; separate suicide-gene, ABT263 and rat arms.